bioMérieux Resultados de beneficios anteriores

Pasado controles de criterios 1/6

bioMérieux ha aumentado sus beneficios a una tasa media anual de 10.8%, mientras que los beneficios de la industria de Medical Equipment han experimentado un crecimiento de 5.1% anual. Los ingresos han ido creciendo a una tasa media de 8.8% al año. La rentabilidad financiera de bioMérieux es de 8.6%, y sus márgenes netos son de 9.7%.

Información clave

10.8%

Tasa de crecimiento de los beneficios

10.9%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	21.6%
Tasa de crecimiento de los ingresos	8.8%
Rentabilidad financiera	8.6%
Margen neto	9.7%
Próxima actualización de resultados	05 Sep 2024

Actualizaciones de resultados anteriores recientes

bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings

Mar 31

There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings

Sep 15

Recent updates

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Mar 15

bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

Jan 27

bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward

Jan 06

A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Dec 16

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Oct 23

bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger

Oct 05

There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings

Sep 15

Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Sep 07

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Jun 30

Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down

Jun 09

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Mar 31

The Return Trends At bioMérieux (EPA:BIM) Look Promising

Feb 23

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

Jan 27

bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet

Dec 16

bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth

Oct 18

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Sep 14

Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital

Aug 11

An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued

Jul 23

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

Jul 05

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

May 26

Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns

May 11

bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year

Apr 23

bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85

Apr 09

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

Mar 25

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Mar 13

I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease

Feb 08

Why We Like The Returns At bioMérieux (EPA:BIM)

Dec 21

Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Dec 07

Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching

Nov 07

Is bioMérieux (EPA:BIM) A Risky Investment?

Oct 07

Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital

Sep 22

Estimating The Fair Value Of bioMérieux S.A. (EPA:BIM)

Sep 07

Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

Aug 06

There's Been No Shortage Of Growth Recently For bioMérieux's (EPA:BIM) Returns On Capital

Jun 15

A Look At The Fair Value Of bioMérieux S.A. (EPA:BIM)

May 31

Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

Apr 30

bioMérieux (EPA:BIM) Could Easily Take On More Debt

Mar 28

The Trend Of High Returns At bioMérieux (EPA:BIM) Has Us Very Interested

Mar 13

Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Feb 25

If You Had Bought bioMérieux (EPA:BIM) Shares Five Years Ago You'd Have Earned 237% Returns

Feb 09

If You Like EPS Growth Then Check Out bioMérieux (EPA:BIM) Before It's Too Late

Jan 20

Could The Market Be Wrong About bioMérieux S.A. (EPA:BIM) Given Its Attractive Financial Prospects?

Dec 30

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Dec 17

Has bioMérieux (EPA:BIM) Got What It Takes To Become A Multi-Bagger?

Dec 03

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero bioMérieux. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

ENXTPA:BIM Ingresos, gastos y beneficios (EUR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	3,675	358	1,021	460
30 Sep 23	3,688	372	1,019	463
30 Jun 23	3,701	386	1,017	466
31 Mar 23	3,645	419	986	456
31 Dec 22	3,589	452	955	447
30 Sep 22	3,525	502	916	429
30 Jun 22	3,460	552	877	412
31 Mar 22	3,418	577	846	399
31 Dec 21	3,376	601	816	386
30 Sep 21	3,296	555	801	381
30 Jun 21	3,216	509	786	377
31 Mar 21	3,167	457	788	388
31 Dec 20	3,118	404	789	399
30 Sep 20	2,997	355	784	399
30 Jun 20	2,876	305	778	398
31 Mar 20	2,775	289	764	386
31 Dec 19	2,675	273	750	374
30 Sep 19	2,601	268	721	362
30 Jun 19	2,527	263	693	350
31 Mar 19	2,474	260	668	338
31 Dec 18	2,421	257	643	327
30 Sep 18	2,372	264	626	320
30 Jun 18	2,323	271	609	312
31 Mar 18	2,306	255	607	308
31 Dec 17	2,288	238	604	304
30 Sep 17	2,262	216	604	300
30 Jun 17	2,237	195	604	295
31 Mar 17	2,170	187	587	283
31 Dec 16	2,103	179	570	272
30 Sep 16	2,068	158	555	260
30 Jun 16	2,032	137	540	249
31 Mar 16	1,998	124	534	244
31 Dec 15	1,965	111	529	239
30 Sep 15	1,908	127	510	230
30 Jun 15	1,851	144	492	222
31 Mar 15	1,775	140	472	214
31 Dec 14	1,698	135	453	206
30 Sep 14	1,656	135	437	201
30 Jun 14	1,614	135	422	196
31 Mar 14	1,601	150	413	191
31 Dec 13	1,588	164	405	186
30 Sep 13	1,581	150	407	184
30 Jun 13	1,574	135	410	182

Ingresos de calidad: BIM tiene un gran one-off loss de €133.3M impacto en sus últimos 12 meses de resultados financieros a 31st December, 2023.

Margen de beneficios creciente: Los actuales márgenes de beneficio(9.7%) de BIM son inferiores a los del año pasado (12.6%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de BIM han crecido un 10.8% al año en los últimos 5 años.

Acelerando crecimiento: BIM ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: BIM tuvo un crecimiento negativo de los beneficios (-21%) durante el año pasado, lo que dificulta la comparación con la media de la industria Medical Equipment (-0.04%).

bioMérieux Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Información clave

Actualizaciones de resultados anteriores recientes

bioMérieux S.A. to Report First Half, 2024 Results on Sep 05, 2024

bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS misses analyst expectations

There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings

First half 2023 earnings released: EPS: €1.37 (vs €1.93 in 1H 2022)

Third quarter 2022 earnings released: EPS: €0.95 (vs €1.37 in 3Q 2021)

Recent updates

Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)

bioMérieux S.A. to Report First Half, 2024 Results on Sep 05, 2024

Now 21% undervalued

bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings

New minor risk - Earnings quality

Dividend of €0.85 announced

bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS misses analyst expectations

bioMérieux S.A., Annual General Meeting, May 23, 2024

bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings

bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward

A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well

bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger

There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings

Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

First half 2023 earnings released: EPS: €1.37 (vs €1.93 in 1H 2022)

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down

Upcoming dividend of €0.85 per share at 0.9% yield

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Third quarter 2022 earnings released: EPS: €0.95 (vs €1.37 in 3Q 2021)

The Return Trends At bioMérieux (EPA:BIM) Look Promising

bioMérieux Introduces GENE-UP ENVIROPRO

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

bioMérieux S.A. to Report Fiscal Year 2022 Results on Mar 08, 2023

bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet

bioMérieux and Jackson Family Wines Introduces Innovation for Wine Quality - BOTTLESAFE™

bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth

Is bioMérieux (EPA:BIM) Using Too Much Debt?

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: €1.93 (vs €2.34 in 1H 2021)

Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital

Now 20% undervalued

An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued

Now 22% undervalued

Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?

Upcoming dividend of €0.85 per share

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

bioMérieux Receives Health Canada Approval for BIOFIRE® Blood Culture Identification 2 (BCID2) Panel for Rapid Molecular Bloodstream Infection Identification

bioMérieux Receives Health Canada Approval for BIOFIRE® Blood Culture Identification 2 (BCID2) Panel for Rapid Molecular Bloodstream Infection Identification

Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns

Insufficient new directors

bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year

bioMérieux S.A., Annual General Meeting, May 23, 2022

bioMérieux S.A. (ENXTPA:BIM) entered into an agreement to acquire remaining unknown shares in Specific Diagnostics, LLC for €360 million.

bioMérieux S.A. (ENXTPA:BIM) entered into an agreement to acquire Specific Diagnostics, LLC.

bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85

bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85

Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?

Price target decreased to €118

Full year 2021 earnings: EPS and revenues exceed analyst expectations

I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease

Why We Like The Returns At bioMérieux (EPA:BIM)

Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)

Price target increased to €124

Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching

Is bioMérieux (EPA:BIM) A Risky Investment?

bioMérieux Achieves First-Ever AOAC INTERNATIONAL Approval for PCR Multiplex Detection of STEC and Salmonella in Cannabis Flower for the GENE-UP® PRO STEC/ Salmonella Assay

Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital

Estimating The Fair Value Of bioMérieux S.A. (EPA:BIM)

First half 2021 earnings released: EPS €2.34 (vs €1.46 in 1H 2020)

Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

There's Been No Shortage Of Growth Recently For bioMérieux's (EPA:BIM) Returns On Capital

A Look At The Fair Value Of bioMérieux S.A. (EPA:BIM)

Upcoming dividend of €0.62 per share

Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today

Full year 2020 earnings released: EPS €3.42 (vs €2.31 in FY 2019)

Desglose de ingresos y gastos
Beta